Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation
David J. Seiffge,Maurizio Paciaroni,Duncan Wilson,Masatoshi Koga,Kosmas Macha,Manuel Cappellari,Sabine Schaedelin,Clare Shakeshaft,Masahito Takagi,Georgios Tsivgoulis,Bruno Bonetti,Bernd Kallmünzer,Shoji Arihiro,Andrea Alberti,Alexandros A. Polymeris,Gareth Ambler,Sohei Yoshimura,Michele Venti,Leo H. Bonati,Keith W. Muir,Hiroshi Yamagami,Sebastian Thilemann,Riccardo Altavilla,Nils Peters,Manabu Inoue,Tobias Bobinger,Giancarlo Agnelli,Martin M. Brown,Shoichiro Sato,Monica Acciarresi,Hans Rolf Jager,Paolo Bovi,Stefan Schwab,Philippe Lyrer,Valeria Caso,Kazunori Toyoda,David J. Werring,Stefan T. Engelter,Gian Marco De Marchis,RAF on behalf of the CROMIS‐2,
DOI: https://doi.org/10.1002/ana.25489
IF: 11.2
2019-04-30
Annals of Neurology
Abstract:OBJECTIVE: We compared outcomes after treatment with direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) in patients with atrial fibrillation (AF) and a recent cerebral ischemia.METHODS: We conducted an individual patient data analysis of seven prospective cohort studies. We included patients with AF and a recent cerebral ischemia (<3 months before starting oral anticoagulation) and a minimum follow-up of 3 months. We analyzed the association between type of anticoagulation (DOAC versus VKA) with the composite primary endpoint (recurrent ischemic stroke [AIS], intracerebral hemorrhage [ICH], or mortality) using mixed-effects Cox proportional hazards regression models; we calculated adjusted hazard ratios (HRs) with 95% confidence intervals (95% CIs).RESULTS: We included 4,912 patients (median age, 78 years [interquartile range {IQR}, 71-84]; 2,331 [47.5%] women; median National Institute of Health Stroke Severity Scale at onset, 5 [IQR, 2-12]); 2,256 (45.9%) patients received VKAs and 2,656 (54.1%) DOACs. Median time from index event to starting oral anticoagulation was 5 days (IQR, 2-14) for VKAs and 5 days (IQR, 2-11) for DOACs (p = 0.53). There were 262 acute ischemic strokes (AISs; 4.4%/year), 71 intracranial hemorrrhages (ICHs; 1.2%/year), and 439 deaths (7.4%/year) during the total follow-up of 5,970 patient-years. Compared to VKAs, DOAC treatment was associated with reduced risks of the composite endpoint (HR, 0.82; 95% CI, 0.67-1.00; p = 0.05) and ICH (HR, 0.42; 95% CI, 0.24-0.71; p < 0.01); we found no differences for the risk of recurrent AIS (HR, 0.91; 95% CI, 0.70-1.19; p = 0.5) and mortality (HR, 0.83; 95% CI, 0.68-1.03; p = 0.09).INTERPRETATION: DOAC treatment commenced early after recent cerebral ischemia related to AF was associated with reduced risk of poor clinical outcomes compared to VKA, mainly attributed to lower risks of ICH. ANN NEUROL 2019;85:823-834.
neurosciences,clinical neurology